SCHEMBL7716769

SCHEMBL7716769

CCOC(=O)C(CC)CP(=O)(O)O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
FOLH1 Q04609 10/20 0.41
NAALAD2 Q9Y3Q0 1/20 0.38
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
KMT2A Q03164 1/20 0.37
LAP3 P28838 1/20 0.37
EPHX2 P34913 1/20 0.36
PPARG P37231 1/20 0.36
HSD17B10 Q99714 2/20 0.36
CPB2 Q96IY4 1/20 0.36
GCLC P48506 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL27426833 0.85 ALDH1A1 (0.42) CYP2D6CYP2C9CYP2C19ALDH1A1MEN1
SCHEMBL7715879 0.83 HSD17B10 (0.38) CYP2D6CYP2C9CYP2C19FOLH1ALDH1A1
SCHEMBL27334920 0.82 HSD17B10 (0.51) CYP2D6CYP2C9CYP2C19FOLH1NAALAD2
SCHEMBL7718813 0.80 CYP2D6 (0.44) CYP2D6CYP2C9CYP2C19FOLH1ALDH1A1
SCHEMBL17504782 0.80 L3MBTL1 (0.46) CYP2D6CYP2C9CYP2C19FOLH1NAALAD2
SCHEMBL284647 0.79 ALDH1A1 (0.50) ALDH1A1MEN1NPC1KMT2AEPHX2
SCHEMBL7718882 0.79 CYP2D6 (0.39) CYP2D6CYP2C9CYP2C19ALDH1A1MEN1
SCHEMBL28237270 0.78 GCLC (0.44) CYP2D6CYP2C9CYP2C19ALDH1A1MEN1
SCHEMBL1304145 0.78 FOLH1 (0.64) FOLH1NAALAD2GCLC
SCHEMBL7717035 0.77 ALDH1A1 (0.48) CYP2D6CYP2C9CYP2C19ALDH1A1CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115536719-B Synthesis method of high-purity plant source 7-ketolithocholic acid 江苏佳尔科药业集团股份有限公司 2024-02-09 CN disclosed
CN-105009349-B Lithium secondary battery 日立麦克赛尔株式会社 2017-09-05 CN disclosed
CN-103515666-B Lithium secondary battery 日立麦克赛尔株式会社 2017-03-01 CN disclosed
CN-105576279-A Lithium secondary battery HITACHI MAXELL 2016-05-11 CN disclosed
CN-102244294-B Nonaqueous electrolyte solution and nonaqueous electrolyte battery MITSUBISHI CHEMICAL CORP. (JP) 2015-11-18 CN disclosed
CN-105009349-A Lithium secondary battery HITACHI MAXELL 2015-10-28 CN disclosed
CN-103647108-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery MITSUBISHI CHEM CORP 2014-03-19 CN disclosed
CN-103515666-A Lithium secondary battery HITACHI MAXELL 2014-01-15 CN disclosed
CN-103038928-A Lithium secondary battery HITACHI MAXELL ENERGY LTD 2013-04-10 CN disclosed
CN-102780038-A Nonaqueous electrolyte battery MITSUBISHI CHEM CORP 2012-11-14 CN disclosed
CN-102244294-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery MITSUBISHI CHEM CORP 2011-11-16 CN disclosed
CN-101622751-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery MITSUBISHI CHEM CORP 2010-01-06 CN disclosed
CN-101454938-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery MITSUBISHI CHEM CORP (JP) 2009-06-10 CN disclosed
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed